<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01027260</url>
  </required_header>
  <id_info>
    <org_study_id>R10-257</org_study_id>
    <nct_id>NCT01027260</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Role of Itopride HCI in Patients With Irritable Bowel Syndrome With Predominant Constipation</brief_title>
  <official_title>A Randomized, Placebo Controlled Study on the Efficacy of Itopride HCI on Irritable Bowel in Patients of Irritable Bowel Syndrome With Constipation (IBS-C)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients suffering from Irritable Bowel Syndrome with predominant constipation will be
      provided with the study medication. The study medication will be evaluated for its efficacy
      in relieving the symptoms
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patients will be asked a simple but well validated question &quot;If there is a satisfactory relief of the symptoms&quot;</measure>
    <time_frame>2 weeks and 4 weeks after the start of the treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subjects will be assessed based on Irritable Bowel Syndrome Severity Score (IBSSS).</measure>
    <time_frame>2 weeks and 4 weeks after the start of the treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety based on the laboratory tests before and at the end of the treatment.</measure>
    <time_frame>4 weeks during the treatment period and 4 weeks following post- therapy period.</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">268</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>Itopride 50 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Itopride 100 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itopride HCI 50 mg</intervention_name>
    <description>Variable dosing</description>
    <arm_group_label>Itopride 50 mg</arm_group_label>
    <other_name>ABT-654</other_name>
    <other_name>Itopride HCI</other_name>
    <other_name>Ganaton</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itopride HCI 100 mg</intervention_name>
    <description>Variable dosing</description>
    <arm_group_label>Itopride 100 mg</arm_group_label>
    <other_name>ABT-654</other_name>
    <other_name>Itopride HCI</other_name>
    <other_name>Ganaton</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Variable dosing</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female patient fulfilling the Rome III criteria for IBS-C

          2. Signed informed consent at screening visit

        Exclusion Criteria:

          1. Patients having significant diarrhea at least 25% of the time during the past 3 months

          2. Patients having alarm symptoms or signs

          3. Chronic diarrhea

          4. History of gastrointestinal haemorrhage, mechanical obstruction or perforation

          5. Patient with clinically relevant ECG abnormalities (prolonged QT interval)

          6. Active psychiatric disorder that would interfere with the study objectives

          7. Health conditions (e.g. age related impairment of cognitive functions) that would
             interfere with the study objectives or might impair the compliance of the patient

          8. Severe hepatic, renal, cardiac, metabolic, haematological or malignant diseases
             (including prolactin dependent tumours) or clinically relevant deviations in
             laboratory values (AST/ALT greater than twice the upper limit of normal, serum
             creatinine * 2 mg/dl [177 Âµmol/l] according to the medical judgement of the
             investigator

          9. Patient with hypokalemia (serum potassium &lt; 3.5 mmol/l).

         10. History of any known hypersensitivity to the ingredients of the investigational drug

         11. Pregnancy or lactation

         12. Women with childbearing potential who do not apply a medically accepted method of
             contraception.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 5870</name>
      <address>
        <city>Karachi</city>
        <zip>74800</zip>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 21441</name>
      <address>
        <city>Karachi</city>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 6130</name>
      <address>
        <city>Lahore</city>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 8535</name>
      <address>
        <city>Rawalpindi</city>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 4, 2009</study_first_submitted>
  <study_first_submitted_qc>December 4, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2009</study_first_posted>
  <last_update_submitted>June 17, 2013</last_update_submitted>
  <last_update_submitted_qc>June 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Constipation</mesh_term>
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

